SCHEMBL12366396

SCHEMBL12366396

[C-]#[N+]c1c(C(F)(F)F)cc(-c2ccccc2)n(Cc2cccc(F)c2)c1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 2/20 0.41
NR1H2 P55055 2/20 0.41
NR1H3 Q13133 2/20 0.41
MAPK14 Q16539 1/20 0.41
GRIN1 Q05586 1/20 0.40
GRIN2B Q13224 1/20 0.40
IDO1 P14902 2/20 0.40
POLB P06746 2/20 0.40
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 2/20 0.39
HTT P42858 1/20 0.39
MAPT P10636 4/20 0.39
EPHX2 P34913 1/20 0.38
PPARG P37231 1/20 0.38
HSD17B10 Q99714 2/20 0.38
CNR1 P21554 1/20 0.38
PKM P14618 1/20 0.38
HPGD P15428 1/20 0.38
CLPP Q16740 2/20 0.38
LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12366212 0.91 CNR1 (0.44) RXRANR1H2NR1H3ALDH1A1KDM4E
SCHEMBL12366418 0.90 MAPT (0.42) RXRANR1H2NR1H3GRIN1GRIN2B
SCHEMBL12366278 0.89 MAPT (0.45) POLBALDH1A1KDM4EMAPTPPARG
SCHEMBL12366308 0.89 RXRA (0.43) RXRANR1H2NR1H3ALDH1A1KDM4E
SCHEMBL12366241 0.88 CNR1 (0.42) POLBALDH1A1KDM4EHTTMAPT
SCHEMBL12366441 0.88 LMNA (0.43) RXRANR1H2NR1H3POLBALDH1A1
SCHEMBL12366421 0.87 RXRA (0.39) RXRANR1H2NR1H3ALDH1A1KDM4E
SCHEMBL12366238 0.86 DCTPP1 (0.42) RXRANR1H2NR1H3ALDH1A1KDM4E
SCHEMBL12366226 0.85 RGS4 (0.43) GRIN1GRIN2BMAPTCNR1LMNA
SCHEMBL12366275 0.84 CFTR (0.42) RXRANR1H2NR1H3KDM4EPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7998986-B2 Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors EXELIXIS PATENT COMPANY LLC (US) 2011-08-16 US disclosed